• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Perioperative Nivolumab in Resectable Lung Cancer

byDaniel GoldshteinandSze Wah Samuel Chan
May 20, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the chemotherapy group with HR 0.58 (significant).

2. Grade 3-4 treatment-related adverse events occurred in 32.5% in the nivolumab group vs 25.2% in the chemotherapy group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nivolumab, an anti-PD-1 antibody, combined with chemotherapy, has been used as neoadjuvant treatment for resectable non-small-cell lung cancer (NSCLC). Recently perioperative approaches, involving both neoadjuvant and adjuvant immunotherapy, have shown promising results in reducing disease relapse and improving overall survival. This study investigated perioperative nivolumab vs chemotherapy in patients with resectable NSCLC. The primary endpoint was event-free survival (EFS) and secondary endpoints included objective response rate (ORR), quality of life (QoL), and safety. The 18-month EFS was 70.2% in the nivolumab group and 50.0% in the chemotherapy group with HR 0.58 (significant), however in the subgroup with tumor PD-L1 expression of less than 1%, the HR was 0.73 (non-significant). The ORR found pCR occurred in 25.3% in the nivolumab group vs 4.7% in the chemotherapy group with OR 6.64 (significant), and pPR occurred in 35.4% in the nivolumab group vs 12.1% in the chemotherapy group with OR 4.01 (significant). QoL change from baseline was not considered to be clinically meaningful in either group, but time until definitive deterioration in disease-related symptoms was 40.0 months in the nivolumab group vs 31.1 months in the chemotherapy group with HR 0.66 (significant). With regards to safety, grade 3-4 treatment-related adverse events occurred in 32.5% in the nivolumab group vs 25.2% in the chemotherapy group; the most common grade 3-4 event was decreased neutrophil count (10.1% vs 6.5%, respectively). The strengths of this study included its methodology and sample size, and the limitations included lack of overall survival data. Overall, this study found that perioperative nivolumab had some improved outcomes compared to chemotherapy alone in patients with resectable stage IIA to IIIB NSCLC.

Click to read the study in NEJM

Relevant Reading: Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Taletrectinib in ROS1 mutated Non–Small Cell Lung Cancer

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

In-Depth [randomized controlled trial]: This international, phase III, double-blind study enrolled adults with stage IIA to IIIB NSCLC and randomized them (1:1) to two treatment arms; the nivolumab arm (neoadjuvant nivolumab with platinum-doublet chemotherapy followed by adjuvant nivolumab, n = 229), and the chemotherapy arm (neoadjuvant placebo with platinum-doublet chemotherapy followed by adjuvant placebo, n = 232). Complete neoadjuvant treatment was completed in 84.7% of the nivolumab group vs 88.4% of the chemotherapy group. Definitive surgery occurred in 77.7% of the nivolumab group vs 76.7% in the chemotherapy group, and R0 resection occurred in 89.3% and 90.4% respectively. The median follow-up was 25.4 months. The 18-month EFS was 70.2% in the nivolumab group and 50.0% in the chemotherapy group with HR 0.58 (95%CI, 0.42-0.81, p<0.001), however in the subgroup with tumor PD-L1 expression of less than 1%, the HR was 0.73 (95%CI, 0.47-1.15). The ORR found pCR occurred in 25.3% (95%CI, 19.8-31.5) in the nivolumab group vs 4.7% (95%CI, 2.4-8.3) in the chemotherapy group with OR 6.64 (95%CI, 3.40-12.97), and pPR occurred in 35.4% (95%CI, 29.2-41.9) in the nivolumab group vs 12.1% (95%CI, 8.2-17.0), in the chemotherapy group with OR 4.01 (95%CI, 2.48-6.49). QoL change from baseline was not considered to be clinically meaningful in either group, but the time until definitive deterioration in disease-related symptoms was 40.0 months (95%CI, 33.6-NA) in the nivolumab group vs 31.1 months (95%CI, 25.0-NA) in the chemotherapy group with HR 0.66 (95% CI, 0.45-0.98). With regards to safety, grade 3-4 treatment-related adverse events occurred in 32.5% in the nivolumab group vs 25.2% in the chemotherapy group; the most common grade 3-4 event was decreased neutrophil count (10.1% vs 6.5%, respectively). Overall, this study found that perioperative nivolumab had some improved outcomes compared to chemotherapy alone in patients with resectable stage IIA to IIIB NSCLC.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: early stage lung cancerNivolumabnsclc
Previous Post

#VisualAbstract: Intra-Articular Platelet-Rich Plasma Injection After Anterior Cruciate Ligament Reconstruction has No Impact on Recovery

Next Post

Female physicians associated with improved inpatient mortality and readmission rates

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Fluorophores enhance visualization for image-guided surgery [PreClinical]
Chronic Disease

Taletrectinib in ROS1 mutated Non–Small Cell Lung Cancer

April 7, 2025
Development of a risk index for colorectal cancer screening
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC

January 13, 2025
Next Post

Female physicians associated with improved inpatient mortality and readmission rates

Primary thromboembolism prophylaxis may be effective in advanced cancer

Genomic data optimizes hematopoietic stem-cell transplantation (HSCT) timing for myelodysplastic syndromes (MDS) and improves patient outcomes

#VisualAbstract: Thrombectomy Plus Medical Care Resulted in Better Functional Outcomes and Lower Mortality than Medical Care Alone in Patients with Stroke with a Large Infarct

#VisualAbstract: Thrombectomy Plus Medical Care Resulted in Better Functional Outcomes and Lower Mortality than Medical Care Alone in Patients with Stroke with a Large Infarct

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.